Autopsy report · NCT03417076

Absolute Bioavailability Study With Bexagliflozin

“Sponsor decision to not initiate study due to sufficient bioavailability information”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Theracos

Sponsor type

Industry

Conditions

Type 2 Diabetes Mellitus

Interventions

Bexagliflozin

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• AndraTec PMCF Study : Investigating the AndraTec Guidewires,PTA Balloons and Stents in Iliac Disease.
  “Sponsor did not pusue with the study” (77% match in meaning)
• Consolidation Therapy in Patients With Metastatic Solid Malignancies
  “Sponsor decision to discontinue study.” (74% match in meaning)
• Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients with Chronic Pain
  “Sponsor decision to stop the study” (74% match in meaning)
• Evaluating Return to Continence and Potency Following Radical Prostatectomy
  “The sponsor decided to not move forward with this study” (74% match in meaning)
• Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer
  “Sponsor decided not to pursue study” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.